Baricitinib Attenuates IFN-γ and Polyinosinic:Polycytidylic Acid-Induced Mitochondrial Damage and Inflammasome Activation in Human Keratinocytes

The study explored the impact of baricitinib, a JAK inhibitor, on mitochondrial damage and inflammasome activation in human keratinocytes, particularly in the context of alopecia areata (AA). It was found that baricitinib effectively inhibited the JAK/STAT pathway, reduced mitochondrial DNA damage, and decreased reactive oxygen species (ROS) levels, which prevented the activation of the NLRP3 inflammasome and led to reduced IL-1β secretion. This indicated that baricitinib could mitigate inflammatory responses in AA. The research underscored the potential of JAK inhibitors in addressing mitochondrial and oxidative stress-related mechanisms in AA pathogenesis, suggesting their benefit in managing keratinocyte inflammation.